PART 01: EXECUTIVE SUMMARY PART 02: SCOPE OF THE REPORT PART 03: RESEARCH METHODOLOGY PART 04: MARKET LANDSCAPE • Market ecosystem • Market characteristics • Market segmentation analysis PART 05: PIPELINE ANALYSIS • Pain management pipeline PART 06: MARKET SIZING • Market definition • Market sizing 2017 • Market size and forecast 2017-2022 PART 07: FIVE FORCES ANALYSIS • Bargaining power of buyers • Bargaining power of suppliers • Threat of new entrants • Threat of substitutes • Threat of rivalry • Market condition PART 08: MARKET SEGMENTATION BY PAIN TYPES • Segmentation by pain types • Nociceptive pain • Neuropathic pain • Psychogenic pain PART 09: MARKET SEGMENTATION BY PRODUCT • Segmentation by product • Comparison by product • Opioids – Market size and forecast 2017-2022 • NSAIDs – Market size and forecast 2017-2022 • Others – Market size and forecast 2017-2022 • Market opportunity by product PART 10: CUSTOMER LANDSCAPE PART 11: REGIONAL LANDSCAPE • Geographical segmentation • Regional comparison • Americas – Market size and forecast 2017-2022 • EMEA – Market size and forecast 2017-2022 • APAC – Market size and forecast 2017-2022 • Market opportunity PART 12: DECISION FRAMEWORK PART 13: DRIVERS AND CHALLENGES • Market drivers • Market challenges PART 14: MARKET TRENDS • Increase in prevalence of pain associated with chronic diseases • Significant increase in the use of opioids for pain management • Novel drug delivery systems and novel targets for pain management PART 15: VENDOR LANDSCAPE • Overview • Landscape disruption PART 16: VENDOR ANALYSIS • Vendors covered • Vendor classification • Market positioning of vendors • Endo Pharmaceuticals • GlaxoSmithKline • Johnson & Johnson • Pfizer PART 17: APPENDIX • List of abbreviations PART 18: EXPLORE TECHNAVIO Exhibit 01: Parent market Exhibit 02: Global CNS therapeutics market Exhibit 03: Market characteristics Exhibit 04: Market segments Exhibit 05: Pain management pipeline 2017-2018 Exhibit 06: Market definition – Inclusions and exclusions checklist Exhibit 07: Market size 2017 Exhibit 08: Validation techniques employed for market sizing 2017 Exhibit 09: Global pain management drugs market – Market size and forecast 2017-2022 ($ mn) Exhibit 10: Global pain management drugs market – Year-over-year growth 2018-2022 (%) Exhibit 11: Five forces analysis 2017 Exhibit 12: Five forces analysis 2022 Exhibit 13: Bargaining power of buyers Exhibit 14: Bargaining power of suppliers Exhibit 15: Threat of new entrants Exhibit 16: Threat of substitutes Exhibit 17: Threat of rivalry Exhibit 18: Market condition – Five forces 2017 Exhibit 19: Global pain management drugs market by product – Market share 2017-2022 (%) Exhibit 20: Comparison by product Exhibit 21: Opioids – Market size and forecast 2017-2022 ($ mn) Exhibit 22: Opioids – Year-over-year growth 2018-2022 (%) Exhibit 23: NSAIDs – Market size and forecast 2017-2022 ($ mn) Exhibit 24: NSAIDs – Year-over-year growth 2018-2022 (%) Exhibit 25: Others – Market size and forecast 2017-2022 ($ mn) Exhibit 26: Selected current other types of drugs for neuropathic pain Exhibit 27: Others – Year-over-year growth 2018-2022 (%) Exhibit 28: Market opportunity by product Exhibit 29: Customer landscape Exhibit 30: Global pain management drugs market by geography – Market share 2017-2022 (%) Exhibit 31: Regional comparison Exhibit 32: Americas – Market size and forecast 2017-2022 ($ mn) Exhibit 33: Americas – Year-over-year growth 2018-2022 (%) Exhibit 34: Top 3 countries in Americas Exhibit 35: EMEA – Market size and forecast 2017-2022 ($ mn) Exhibit 36: EMEA – Year-over-year growth 2018-2022 (%) Exhibit 37: Top 3 countries in EMEA Exhibit 38: APAC – Market size and forecast 2017-2022 ($ mn) Exhibit 39: APAC – Year-over-year growth 2018-2022 (%) Exhibit 40: Top 3 countries in APAC Exhibit 41: Market opportunity Exhibit 42: Increasing geriatric population in Europe Exhibit 43: Percentage of older Americans experiencing chronic pain conditions 2014 Exhibit 44: Some of the recently approved drugs by the US FDA for pain management Exhibit 45: Some of the novel abuse-deterrent opioids and monoclonal antibodies Exhibit 46: Vendor landscape Exhibit 47: Landscape disruption Exhibit 48: Vendors covered Exhibit 49: Vendor classification Exhibit 50: Market positioning of vendors Exhibit 51:  Endo Pharmaceuticals: An overview Exhibit 52:  Endo Pharmaceuticals – Business segments Exhibit 53:  Endo Pharmaceuticals – Organizational developments Exhibit 54:  Endo Pharmaceuticals – Segment focus Exhibit 55: Endo Pharmaceuticals – Key offerings Exhibit 56: GlaxoSmithKline: An overview Exhibit 57: GlaxoSmithKline – Business segments Exhibit 58: GlaxoSmithKline – Organizational developments Exhibit 59: GlaxoSmithKline – Geographic focus Exhibit 60: GlaxoSmithKline – Key offerings Exhibit 61: Johnson & Johnson: An overview Exhibit 62: Johnson & Johnson – Business segments Exhibit 63: Johnson & Johnson – Organizational developments Exhibit 64: Johnson & Johnson – Geographic focus Exhibit 65: Johnson & Johnson – Segment focus Exhibit 66: Johnson & Johnson – Key offerings Exhibit 67:  Pfizer: An overview Exhibit 68: Pfizer – Business segments Exhibit 69:  Pfizer – Organizational developments Exhibit 70: Pfizer – Geographic focus Exhibit 71:  Pfizer – Segment focus Exhibit 72:  Pfizer – Key offerings    

Endo Pharmaceuticals GlaxoSmithKline Johnson & Johnson Pfizer